Education
About Us
Working with TipRanks
Follow Us
Ikena Oncology (IKNA)
NASDAQ:IKNA
IKNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.22 - $1.94
Previous CloseN/A
Volume99.58K
Average Volume (3M)134.26K
Market Cap
$53.95M
Enterprise Value-$46.15M
Total Cash (Recent Filing)$82.08M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Mar 18, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding40,258,410
10 Day Avg. Volume82,288
30 Day Avg. Volume134,261
Standard Deviation0.24
R-Squared0.00902
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)98.13
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.67
Enterprise Value/Ebitda0.73
Forecast
1Y Price Target
$4.00Price Target Upside198.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Ikena Oncology News
PremiumCompany Announcements
Ikena Oncology and Inmagene Announce Merger and Fundraising
PremiumCompany Announcements
Ikena Oncology Reports Strategic Realignment and Financial Performance
PremiumCompany Announcements
Ikena Oncology Promotes Jotin Marango to Chief Operating Officer---
Bulls Say, Bears Say
Bulls Say
Development Of IK-595Ikena's development of IK-595 remains on track, as a promising and novel MAPK-targeted asset.
Preclinical Study ResultsPreclinical studies have demonstrated that IK-595 induces significant tumor pharmacodynamics (PD) and shows antitumor effects in certain mouse xenograft models.
Therapeutic Index And Binding AffinityIK-595 exhibits a higher therapeutic index and superior binding affinity to the MEK-RAF complex compared to other inhibitors targeting the MAPK pathway.
Bears Say
Stock ValuationThe removal of Ikena’s IK-930 (TEADi) has contributed to the stock’s current valuation near its 52-week low.
Underappreciation By The MarketThe potential of IK-595, a novel dual RAF/MEK inhibitor, continues to be underappreciated by the Street.
Workforce ReductionIkena announced the discontinuation of its lead asset IK-930 along with a ~53% workforce reduction to preserve cash.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IKNA FAQ
What was Ikena Oncology’s price range in the past 12 months?
Ikena Oncology lowest stock price was $1.22 and its highest was $1.94 in the past 12 months.
What is Ikena Oncology’s market cap?
Ikena Oncology’s market cap is $53.95M.
When is Ikena Oncology’s upcoming earnings report date?
Ikena Oncology’s upcoming earnings report date is Mar 18, 2025 which is in 15 days.
How were Ikena Oncology’s earnings last quarter?
Ikena Oncology released its earnings results on Nov 07, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.255 by $0.045.
Is Ikena Oncology overvalued?
According to Wall Street analysts Ikena Oncology’s price is currently Undervalued.
Does Ikena Oncology pay dividends?
Ikena Oncology does not currently pay dividends.
What is Ikena Oncology’s EPS estimate?
Ikena Oncology’s EPS estimate is -0.27.
How many shares outstanding does Ikena Oncology have?
Ikena Oncology has 40,258,410 shares outstanding.
What happened to Ikena Oncology’s price movement after its last earnings report?
Ikena Oncology reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.255. Following the earnings report the stock price went down -1.744%.
Which hedge fund is a major shareholder of Ikena Oncology?
Currently, no hedge funds are holding shares in IKNA
---
Ikena Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (198.51% Upside)
$4.00 (198.51% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.25%
12-Months-Change
Fundamentals
Return on Equity
-37.08%
Trailing 12-Months
Asset Growth
-30.81%
Trailing 12-Months
Company Description
Ikena Oncology
Ikena Oncology Inc is an oncology company. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme Kynase; discovery-stage molecules targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.
---
IKNA Stock 12 Month Forecast
Average Price Target
$4.00
▲(198.51% Upside)
Technical Analysis
Fate Therapeutics
―
Scholar Rock Holding
―
Precision BioSciences
―
IGM Biosciences
―
Thryv Holdings
―
Best Analysts Covering IKNA
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-22.11%
reiterated a buy rating 4 months ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -22.11% per trade.
---